Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.35 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.35 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.35 |
| ▸ | SLC18A2 | Q05940 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4093465 | 1.00 | MEN1 (0.38) | MEN1KMT2AALDH1A1HPGDCYP2C19 | |
| SCHEMBL13723257 | 0.86 | ALDH1A1 (0.40) | MEN1KMT2AALDH1A1HPGDKDM4E | |
| SCHEMBL13724256 | 0.80 | HRH1 (0.34) | MEN1KMT2AALDH1A1HPGDKDM4E | |
| SCHEMBL4089937 | 0.79 | USP2 (0.41) | ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL6403134 | 0.78 | TPSAB1 (0.36) | ALDH1A1HPGDCYP2C19HTTPDK1 | |
| SCHEMBL6403138 | 0.78 | TPSAB1 (0.36) | ALDH1A1HPGDCYP2C19HTTPDK1 | |
| SCHEMBL27839598 | 0.75 | PHGDH (0.44) | MEN1KMT2AALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL13812217 | 0.75 | BIRC2 (0.49) | MEN1KMT2AALDH1A1HPGDCYP2C19 | |
| SCHEMBL6971664 | 0.72 | SLC18A3 (0.49) | MEN1KMT2AALDH1A1KDM4EPOLB | |
| SCHEMBL5953471 | 0.72 | SLC18A3 (0.49) | MEN1KMT2AALDH1A1KDM4EPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090203695-A1 | Compounds IV | BIOVITRUM AB (SE) | 2009-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203695-A1 | Compounds IV | GPR119, FABP4, LIPC | MEN1 2245/4885KMT2A 4312/4885ALDH1A1 2629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.